TAPI-0

• Description:

  TAPI-0 is a TACE (TNF-α converting enzyme; ADAM17) inhibitor with an IC50 of 100 nM. TAPI-0 is a MMP inhibitor and also attenuates TNF-α processing[1][2].

• UNSPSC:

  12352209

• Hazard Statement:

  H301

• Target:

  Bacterial; MMP; TNF Receptor

• Type:

  Reference compound

• Related Pathways:

  Anti-infection; Apoptosis; Metabolic Enzyme/Protease

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Cancer; Infection

• Assay Protocol:

  https://www.medchemexpress.com/tapi-0.html

• Purity:

  98.98

• Solubility:

  DMSO : 50 mg/mL (ultrasonic)

• Smiles:

  ONC(C[C@H](C(N[C@H](C(N[C@H](C(N)=O)C)=O)CC1=CC2=C(C=C1)C=CC=C2)=O)CC(C)C)=O

• Molecular Formula:

  C24H32N4O5

• Molecular Weight:

  456.53

• Precautions:

  H301

• References & Citations:

  [1]Amit Balakrishnan, et al. Metalloprotease inhibitors GM6001 and TAPI-0 inhibit the obligate intracellular human pathogen Chlamydia trachomatis by targeting peptide deformylase of the bacterium. J Biol Chem. 2006 Jun 16;281 (24) :16691-9.|[2]Shiori Haga, et al. TACE antagonists blocking ACE2 shedding caused by the spike protein of SARS-CoV are candidate antiviral compounds. Antiviral Res. 2010 Mar;85 (3) :551-5.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [163958-73-4]